Boston Family Office LLC Reduces Stake in The Clorox Company $CLX

Boston Family Office LLC lowered its position in The Clorox Company (NYSE:CLX) by 29.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,203 shares of the company’s stock after selling 7,260 shares during the period. Boston Family Office LLC’s holdings in Clorox were worth $1,735,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Wilkins Investment Counsel Inc. boosted its position in Clorox by 250.6% in the fourth quarter. Wilkins Investment Counsel Inc. now owns 55,064 shares of the company’s stock valued at $5,552,000 after buying an additional 39,360 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Clorox by 27.0% in the third quarter. JPMorgan Chase & Co. now owns 928,654 shares of the company’s stock valued at $114,506,000 after acquiring an additional 197,330 shares during the period. Morningstar Investment Management LLC lifted its holdings in Clorox by 131.8% in the fourth quarter. Morningstar Investment Management LLC now owns 62,454 shares of the company’s stock valued at $6,297,000 after acquiring an additional 35,506 shares during the period. Swiss Life Asset Management Ltd lifted its holdings in Clorox by 221.4% in the third quarter. Swiss Life Asset Management Ltd now owns 86,426 shares of the company’s stock valued at $10,656,000 after acquiring an additional 59,533 shares during the period. Finally, Birch Hill Investment Advisors LLC acquired a new position in Clorox in the fourth quarter valued at approximately $22,103,000. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CLX shares. The Goldman Sachs Group reissued a “sell” rating and issued a $83.00 price target on shares of Clorox in a report on Friday, May 1st. JPMorgan Chase & Co. reduced their target price on Clorox from $99.00 to $95.00 and set an “underweight” rating for the company in a research note on Friday, May 1st. BNP Paribas Exane reduced their target price on Clorox from $128.00 to $97.00 and set a “neutral” rating for the company in a research note on Tuesday, May 12th. Morgan Stanley reduced their target price on Clorox from $110.00 to $97.00 and set an “equal weight” rating for the company in a research note on Friday, May 1st. Finally, Barclays reduced their target price on Clorox from $102.00 to $85.00 and set an “underweight” rating for the company in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Buy rating, eleven have given a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat, Clorox presently has an average rating of “Reduce” and a consensus price target of $103.40.

Insider Buying and Selling at Clorox

In other Clorox news, Director Pierre R. Breber bought 5,000 shares of the business’s stock in a transaction dated Tuesday, May 5th. The shares were acquired at an average price of $85.82 per share, with a total value of $429,100.00. Following the transaction, the director owned 18,000 shares of the company’s stock, valued at approximately $1,544,760. The trade was a 38.46% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.63% of the company’s stock.

Clorox Stock Performance

Shares of Clorox stock opened at $96.74 on Friday. The company has a debt-to-equity ratio of 27.03, a current ratio of 0.84 and a quick ratio of 0.65. The stock has a market capitalization of $11.70 billion, a price-to-earnings ratio of 15.70, a price-to-earnings-growth ratio of 0.51 and a beta of 0.56. The business has a 50-day moving average of $96.43 and a 200 day moving average of $105.20. The Clorox Company has a 12 month low of $84.70 and a 12 month high of $132.03.

Clorox (NYSE:CLX) last posted its quarterly earnings results on Thursday, April 30th. The company reported $1.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.55 by $0.09. The company had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.67 billion. Clorox had a return on equity of 443.64% and a net margin of 11.18%.Clorox’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter last year, the company earned $1.45 EPS. Clorox has set its FY 2026 guidance at 5.450-5.650 EPS. As a group, sell-side analysts forecast that The Clorox Company will post 5.61 earnings per share for the current year.

About Clorox

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.